La fenfluramina mejora la calidad de vida del paciente según Antonioli de UCB Italia.

(Adnkronos) – «Today is a very important day because fenfluramine is finally available in Italy for Lennox-Gastaut syndrome (Lgs). Fenfluramine is capable of decisively and permanently reducing epileptic seizures, and therefore contributes significantly to the quality of life of the patient. family, but also in terms of the comorbidities that accompany this pathology.» These are the words of Laura Antonioli, Head of Medical Affairs at Ucb Italia, at today’s press conference in Milan, announcing the reimbursement of the new indication for fenfluramine in the treatment of Lgs, a severe and progressive epileptic encephalopathy that affects approximately 1 million people worldwide. around the world. «Multidisciplinarity, the transition from pediatric age to adulthood» are themes that the pharmaceutical industry is betting on, Antonioli assures, recalling that special attention is paid to «all those who represent fundamental social care services in the lives of these patients.» «.— [email protected] (Web Information)